NCT07582120
Psilocybin-Assisted Therapy as a Treatment for Depression
StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 6 more changesShow less
- Start date changed from estimate of Jun 2026 to Nov 1, 2026
- Eligibility criteria expanded, about 22 words
- Primary completion date: Jun 2031 to Jun 15, 2031
- Study completion date: Dec 2031 to Dec 15, 2031
- Site details revised
- Publications: details revised at 1 of 1 entry
- Minor Study sites: 0 to 1v3
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Characterize ACUTE (~1 week post-dose) and PERSISTING (~30 days post-dose) effects of PAT in depressed adults at two possible administrations on depression symptom severity using the Montgomery-Asberg Depression Rating Scale (MADRS) score.
Timeframe: 1 week and 30 days post-dose for both administration sessions
Characterize ACUTE (~1 week post-dose) and PERSISTING (~30 days post-dose) effects of PAT in depressed adults at two possible administrations on psychological flexibility using the Multidimensional Psychological Flexibility Inventory (MPFI).
Timeframe: 1 week and 30 days post-dose for both administration sessions
Arms and interventions
25mg Open Label dose of synthetic psilocybinExperimental
Drugs: Psilocybin (Usona Institute)
Sites
1 site in 1 country
- Washington University School of MedicineSt Louis, Missouri, United States